Overview of metabolic syndrome in COVID-19 patients

Abstract

Metabolic syndrome (MetS) is highly prevalent in Indian Subcontinent, andits components like high BMI, diabetes mellitus, and hypertension have been identified as risk factors to develop severe SARS-CoV2 (COVID-19); however, data on MetS and clinical outcomes in COVID-19 are limited. Thisstudy aims to determine association between MetS and disease out-comes, that is, morbidity and mortality among patients with COVID-19. This retrospective mono centric cohort study was performed from. 1st may to 15th may 2021, on 100 patient admitted in a tertiary care hospital. Hospital stay and mortality rates are compared between the Mets and non Mets group. The mean age of participant was 44.5±9 year there is preponderance of male gender was present, among 100 patients 28 were having MetS and 72 were non MetS, Among 28 MetS 5 were remain asymptomatic, 13 were symptomatic with hospital stay less than 14 days and 7 were symptomatic with hospital stay more than 14 days and 3 were died. The findings our study suggest a relationship between patient having MetS are at increased risk of severe complications and mortality among COVID-19 patients.